Private equity firm ADV Partners is to invest Rs 305.7 crore (US$45m) in Chennai-based ophthalmology group Dr. Agarwal, which aims to double its eye hospital network in the next four years.
In a far-reaching interview with a leading financial daily, Bart Malenstein, the young CEO of Bergman Clinics, the largest Dutch private clinic group, reveals the pressures faced by the private clinic sector in the Netherlands. He even goes so far as to say that "more than once" he toyed with the idea of shutting the door and not coming back. He refused to reveal 2014 results which have yet to be published. But he says that Bergman has reached an agreement with Rabobank.
Spanish operator Ribera Salud wants to expand its 35% stake to full ownership in the controversial Alzira-style hospital concession in Dénia, in the Valencian autonomy of Spain. German insurer DKV own the remaining 65% and would almost certainly be willing to sell cheap. The concession is unprofitable, the Valencian government is set to terminate it and, according to Spanish press reports, even refuses to meet the CEO of Ribera. The puzzle is why Ribera and its backer American giant Centene would want to pump more money into what looks like a doomed model.
The rehabilitation market in Germany is consolidating. Median bought four clinics from Lielje Group in December 2015 and Orpea acquired Celenus Kliniken, the third largest provider in the country, in May 2015. But it is unlikely new players will enter the market, for now, says Nikolaos Tavridis, CEO of Axion Consult.
We talked to Charles Woler, who turned around French reference lab Biomnis and is now the CEO of bioDS - Biomnis holding company, part of Eurofins. He sees signs that governments are starting to think the unthinkable and that public sector outsourcing of lab tests could grow. Woler is also a panelist at our annual conference, Breaking Barriers 2016 conference.
Asklepios CFO and Deputy Chairman Stefan Leonhard’s departure from the third largest German hospital chain comes just 10 days after he revealed that a subsidiary had been set up to allow Asklepios owner Bernard gr. Broermann to take a €70m dividend out of the business. In the article, Leonhard also stated that Rhoen shares seemed to him overvalued. That is an odd thing for a finance director to say when his company owns an 18% stake in the listed company in question. What does all this reveal about the true state of management inside Asklepios and about its future?
As the Russian economy struggles to lift itself out of its oily quagmire – the rouble hit a record low of 85 to the dollar this week – private healthcare keeps plugging away. Alarming figures are never far from the press: Medsi profits fell almost 5 times year-on-year and the country’s biggest imaging provider will see them cut to a third. In 2008/09, a third of private clinics went under, but we don’t think things are so bad this time around.
Stefan Leonhard, 54, the CFO and deputy chairman of Asklepios, the big German private hospital group, has quit suddenly after 14 years with the group. The company states in a press release that it regrets his departure. The board agreed to allow Leonhard to terminate a contract which was due to last a further two years and to let him depart at the end of the month. Why?
CARE Hospitals, the Indian chain, has just been bought by the private equity group, Abraaj, in a deal that is rumoured to value the enterprise at 1,850 crores INR (US$273m). Here we speak to CARE’s CEO, Dilip Jose, about future plans and how he expects CARE to function within Abraaj’s international network.
A Chinese conglomerate owned by the country’s richest man is moving into healthcare, reports Jing Daily. Dalian Wanda will invest US$2.3bn in three private hospitals in Shanghai, Chengdu and Qingdao that will be run by the British operator International Hospitals group. The hospitals should open within "the next few years”.
Healthcare Business International users cookies to improve the functionality, performance, and effectiveness of our communications. Detailed information on the use of cookies is provided in our Cookies Policy. By continuing to use this site, or by clicking "I agree" you consent to the use of cookies.
